Skip to Content

Paul Harari

From Human Oncology

Jump to: navigation, search

Harari Paul.png

Paul M. Harari



    Phone: (608) 263-5009

    Mailing Address:
    K4/336, Bx3684 Clinical Science Center
    600 Highland Ave
    Madison, WI 53792

Harari Lab Page

Harari Lab


  • Tufts University, Medford, Massachusetts, Biology: B.S.
  • University of Virginia School of Medicine, Charlottesville, Virginia, M.D.
  • Internal Medicine, University of California Davis, Sacramento, California.
  • Radiation Oncology and Cancer Biology, University of Arizona, Tucson, Arizona.


  • Head and neck cancer
  • Molecular modulation of radiation response
  • Conformal head and neck radiation treatment techniques
  • Molecular inhibition of growth factor receptor signaling

Fields of Interest

  • Radiation Oncology
  • Head and Neck Oncology
  • Oncology Training and Education


  • Professor & Chairman, Department of Human Oncology, University of Wisconsin School of Medicine & Public Health
  • Associate Director, UW Paul P. Carbone Comprehensive Cancer Center
  • Jack Fowler Professor of Human Oncology

Recent Publications

Andrzej P Wojcieszynski, Patrick M Hill, Stephen A Rosenberg, Craig R Hullett, Zacariah E Labby, Bhudatt Paliwal, Mark W Geurts, R Adam Bayliss, John E Bayouth, Paul M Harari, Michael F Bassetti, Andrew M Baschnagel
Dosimetric Comparison of Real-Time MRI-Guided Tri-Cobalt-60 Versus Linear Accelerator-Based Stereotactic Body Radiation Therapy Lung Cancer Plans.
Technol. Cancer Res. Treat.: 2017;1533034617691407

Gopal Iyer, James Price, Shay Bourgeois, Eric Armstrong, Shyhmin Huang, Paul M Harari
Erratum to: Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
BMC Cancer: 2016, 16(1);928

Jeffrey V Brower, Shuai Chen, Michael F Bassetti, Menggang Yu, Paul M Harari, Mark A Ritter, Andrew M Baschnagel
Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012.
Int. J. Radiat. Oncol. Biol. Phys.: 2016, 96(5);985-993

Jérôme Fayette, Lori Wirth, Cristina Oprean, Anghel Udrea, Antonio Jimeno, Danny Rischin, Christopher Nutting, Paul M Harari, Tibor Csoszi, Dana Cernea, Paul O'Brien, William D Hanley, Amy V Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan B Vermorken
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).
Front Oncol: 2016, 6();232

Gopal Iyer, James Price, Shay Bourgeois, Eric Armstrong, Shyhmin Huang, Paul M Harari
Insulin growth factor 1 like receptor (IGF-1R).
BMC Cancer: 2016, 16(1);773